


FORM PTO-1449 (modified)  
 To: U.S. Department of Commerce  
 (PW FORM PAT-1449)  
 Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	059490-5042	ORECZ/P32872US
Applicant: Anders PETTERSSON et al.		
Appln. No.: 10/531,598		
Filing Date: November 25, 2005		
Date: April 11, 2007	Page 1 of 2	Examiner: unassigned Group Art Unit: 1615

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Date: April 11, 2007

Page 1 of 2

**U.S. PATENT DOCUMENTS**

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
/MY/	AR	4,283,408	08/1981	Hirata et al.	424	270	
	BR	5,244,670	09/1993	Upson et al.	242	439	
	CR	5,840,737	11/1998	Phillips	514	338	
	DR	6,013,680	01/2000	Ogawa et al.	514	925	
	ER	6,489,346 B1	12/2002	Phillips	514	338	
	FR	6,645,988 B2	11/2003	Phillips	514	338	
	GR	6,699,885 B2	03/2004	Phillips	514	338	
	HR	2004/0171646 A1	09/2004	Phillips	514	338	
/MY/	IR	2005/0054682 A1	03/2005	Phillips	514	338	

**FOREIGN PATENT DOCUMENTS**

		Document Number		Date MM/YYYY		English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
/MY/	JR	WO 98/40054	09/1998	WIPO	Wendsjö	A61K	X		
/MY/	KR	0 338 861	10/1989	Europe	Spickett et al.	A61K	X		
	LR								

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

/MY/	MR	Gschwantler et al., "Famotidine versus oromeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori – a randomized, controlled trial", Ailment Pharmacol Ther, 13:1063-1069 (1999)	X			
/MY/	NR	Eriksson et al., "Omeprazole and H <sub>2</sub> -receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis", European Journal of Castroenterology & Hepatology, 7(5):467-475 (1995)	X			
/MY/	OR	Hedenström et al., "Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers", Ailment Pharmacol Ther, 11:1137-1141 (1997)	X			
/MY/	PR	Hurlimann et al., "Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole", Ailment Pharmacol Ther, 8:193-201 (1994)	X			
/MY/	QR	Hunyady et al., "Statistical interpretation of the antisecretory effect of famotidine measured by intragastric pH-metry", Eur. J. Clin. Pharmacol., 50:449-456 (1996)	X			

Examiner /Micah Paul Young/ Date Considered: 06/24/2007

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office					Atty. Dkt. No.	M#	Client Ref.			
					059490-5042		ORECZ/P32872US			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>					Applicant: Anders PETTERSSON et al.					
					Appln. No.: 10/531,598					
					Filing Date: November 25, 2005					
					Date: April 11, 2007		Page <b>2</b> of <b>2</b>	Examiner: unassigned	Group Art Unit: 1615	
<b>U.S. PATENT DOCUMENTS</b>										
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)			Class	Sub Class	Filing Date (if appropriate)		
RR										
SR										
TR										
UR										
<b>FOREIGN PATENT DOCUMENTS</b>							English Abstract	Translation Readily Available		
	Document Number	Date MM/YYYY	Country	Inventor Name			Enclosed	No	Enclose	No
VR										
WR										
XR										
YR										
<b>OTHER</b> (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)										
/MY/	ZR	Hoogerwerf et al., "Agents Used for Control of Gastric Acidity and Treatment of Peptic Ulcers and Gastroesophageal Reflux Disease", Goodman & Gilman's, The Pharmacological Basis of Therapeutics (Tenth Edition) McGraw-Hill, published September 2001, pp. 1005-1020					X			
	AAR									
	BBR									
	CCR									
Examiner /Micah Paul Young/			Date Considered: 06/24/2007							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.										

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <small>Use several sheets if necessary)</small>	<b>Attorney Docket No.:</b> <b>3029-1002</b>	<b>Application No.:</b> <b>10/531,598</b>
	<b>Applicant:</b> <b>Anders PETTERSSON et al.</b>	
	<b>Filing Date:</b> <b>April 18, 2005</b>	<b>Group Art Unit:</b> <b>1615</b>

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
/MY/	0 166 287*	1/2/86	European				x
	0 147 726*	7/10/85	European				x
	0 005 129	10/31/79	European				x
	199 25 710*	12/14/00	Germany				x
	2 163 747	3/5/86	Great Britain				
	WO 02/083132	10/24/02	International				
	WO 00/78284	12/28/00	International				
	WO 99/04773	2/4/99	International				
/MY/	WO 97/25066	7/17/97	International				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

/M/	Andersson, T. et al. <i>Br. J. clin. Pharmac.</i> 31, 1991, 275-278
i	Cheng, D. <i>Canadian Pharmaceutical Journal</i> 135, 2002, 27-45
	Hirschowitz, B. et al. <i>Dig. Dis. Sci.</i> 40, 1995, 3S-23S
	Hunt, R. et al. <i>Dig. Dis. Sci.</i> 40, 1995, 24S-49S
	Katz, P. et al. <i>Balliere's Best Practice &amp; Research Clinical Gastroenterology</i> 15, 2001, 371-384
	Nwokolo, C. et al. <i>Ailment Pharmacol. Ther.</i> 4, 1990, 29-45
X	Peghini P. et al. <i>Gastroenterology</i> 115, 1998, 1335-1339
/M/	Richardson, P. et al. <i>Drugs</i> 56, 1998, 307-335

**EXAMINER:** /Micah Paul Young/ **DATE CONSIDERED**

06/24/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

\* English Abstract provided for the Examiner's convenience

<p>012 INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>AUG 18 2005 USPTO MAIL OFFICE</p> <p>(Use several sheets if necessary)</p>	Attorney Docket No.:	Application No.:
	<b>3029-1002</b>	<b>10/531,598</b>
	Applicant:	
	<b>Anders PETTERSSON et al.</b>	
Filing Date:	Group Art Unit:	
<b>April 18, 2005</b>	<b>1615</b>	

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
/MY/	WO 97/25065	7/17/97	International				
/MY/	WO 95/17080	6/22/95	International				
	WO 95/01977	1/19/95	International				
	WO 94/27988	12/8/94	International				
	WO 93/11750	6/24/93	International				
	WO 91/19712	6/26/91	International				
/MY/	WO 91/19711	12/26/91	International				
/MY/	WO 90/06925	6/28/90	International				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

/MY/	Sachs, G. <i>Eur. J. Gastroenterol. Hepatol.</i> 13, 2001, S35-S41
/MY/	Sachs, G. et al. <i>Ann. Rev. Pharmacol. Toxicol.</i> , 35, 1995, 277-305
/MY/	Sachs, G. <i>Pharmacotherapy</i> 17, 1997, 22-37
/MY/	Shin, J. et al. <i>Ann. NY Acad. Sci.</i> 834, 1997, 65-76

<b>EXAMINER:</b> /Micah Paul Young/	<b>DATE CONSIDERED</b> 06/24/2007
--	--------------------------------------

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

\* Abstract provided for the Examiner's convenience